GAZYVA + ST* is
NOW APPROVED
in lupus nephritis[1]

Advancing Care in Lupus Nephritis: Exploring the Evolving Landscape

Join us for a GAZYVA Exhibitor Spotlight

We are pleased to invite you to the GAZYVA Exhibitor Spotlight on November 6 at the American Society of Nephrology (ASN) Kidney Week 2025.

GAZYVA is now FDA approved as an advanced therapy for adults with active lupus nephritis who are receiving standard therapy, representing an advancement in lupus nephritis care.[1]*

Learning Objectives:

- Key efficacy and safety data on GAZYVA, the first and only FDA-approved B-cell depleter in lupus nephritis in combination with standard therapy[1]*

Exhibit Hall D
Theater #1

George R. Brown Convention Center
Houston, TX

November 6, 2025
12:00 PM to 12:45 PM CST

Presenter:

Gerald B. Appel, MD, FASN

Co-Director of Clinical Nephrology

NewYork-Presbyterian Hospital/
Columbia University Medical Center

New York, NY

*Standard therapy (ST) included mycophenolate mofetil (MMF) + corticosteroids.[1]

Indication

GAZYVA® (obinutuzumab) is indicated for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy.

Important Safety Information

BOXED WARNINGS: HEPATITIS B VIRUS REACTIVATION AND PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY

- **Hepatitis B Virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients receiving CD20-directed cytolytic antibodies, including GAZYVA. Screen all patients for HBV infection before treatment initiation. Monitor HBV-positive patients during and after treatment with GAZYVA. Discontinue GAZYVA and concomitant medications in the event of HBV reactivation**
- **Progressive Multifocal Leukoencephalopathy (PML), including fatal PML, can occur in patients receiving GAZYVA**

Please see Important Safety Information on the next page and the full Prescribing Information, including BOXED WARNINGS.

GAZYVA®
obinutuzumab
injection | 1,000mg/40mL

Important Safety Information (cont'd)

Contraindications

- GAZYVA is contraindicated in patients with known hypersensitivity reactions (eg, anaphylaxis) to obinutuzumab or to any of the excipients, or serum sickness with prior obinutuzumab use

Additional Warnings and Precautions

- **Infusion-Related Reactions:** GAZYVA can cause severe and life-threatening infusion-related reactions. Premedicate patients with a glucocorticoid, acetaminophen, and antihistamine. Monitor patients closely during infusions. Interrupt, reduce rate, or discontinue for infusion-related reactions based on severity
- **Hypersensitivity Reactions Including Serum Sickness:** Discontinue GAZYVA permanently
- **Serious, Including Fatal, Infections:** Fatal and serious bacterial, fungal, and new or reactivated viral infections can occur during and following GAZYVA therapy. Do not administer GAZYVA to patients with an active infection. Patients with a history of recurring or chronic infections may be at increased risk of infection. In patients who develop a serious infection while receiving GAZYVA, immediately discontinue GAZYVA and institute appropriate treatment
- **Neutropenia:** Severe and life-threatening neutropenia, including febrile neutropenia, has been reported during treatment with GAZYVA. In patients with Grade 3 to 4 neutropenia, monitor laboratory tests until resolution and for infection. Consider dose delays and infection prophylaxis, as appropriate
- **Thrombocytopenia:** Severe and life-threatening thrombocytopenia and fatal hemorrhagic events have been reported during treatment with GAZYVA in combination with chemotherapy. Monitor for decreased platelet counts and bleeding. Transfusion may be necessary
- **Disseminated Intravascular Coagulation:** Fatal and severe DIC has been reported in patients receiving GAZYVA for treatment of CLL and NHL. Evaluate cause and monitor for bleeding, thrombosis, and need for supportive care
- **Immunization:** Avoid administration of live virus vaccines during GAZYVA treatment and until B-cell recovery
- **Embryo-Fetal Toxicity:** GAZYVA can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception

Additional Important Safety Information

- The most common adverse reactions (incidence ≥5%) observed in patients with LN in the GAZYVA arm were upper respiratory tract infection, COVID-19, urinary tract infection, bronchitis, pneumonia, infusion-related reactions, and neutropenia

You are encouraged to report side effects to Genentech and the FDA. You may contact Genentech by calling 1-888-835-2555. You may contact the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.

Please see the full Prescribing Information for additional Important Safety Information, including BOXED WARNINGS.

Minnesota, Vermont, and Federal Entities (eg, the Department of Defense and the Department of Veterans Affairs) have restrictions on receiving in-kind benefits (eg, meals) at company-sponsored events. You are accountable for understanding such restrictions and complying with them. If you are licensed in or affiliated with any of these states or federal agencies, Genentech policies may restrict you from consuming any portion of the Genentech-sponsored meal at this program.

Please indicate whether you will accept or opt out of Genentech's in-kind benefits (eg, meals) at the program. If you choose to opt out, you may not consume any food or beverage during the program.

For all program attendees who receive Genentech's in-kind benefits at this program, Genentech will report the attendee's name and the value received as required by federal and state disclosure laws (for more information on the federal law please visit sunshine.gene.com).

The meal value reported may vary by event location and be up to $150 per person (exceptions may apply).

This event is supported by Genentech.

The Exhibitor Spotlight is not a continuing education (CE) event and is intended for US healthcare professionals only.

Reference: 1. GAZYVA full Prescribing Information. South San Francisco, CA: Genentech, Inc.; 2025.

Genentech
A Member of the Roche Group

GAZYVA® obinutuzumab injection | 1,000mg/40mL